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Abstract: Prader-Willi syndrome (PWS) is caused by the loss of RNA expression from an imprinted region on chromosome 15 that
includes SNRPN, SNORD115, and SNORD116. Currently, there are no mouse models that faithfully reflect the human phenotype and
investigations rely on human post-mortem material. During molecular characterization of tissue deposited in a public brain bank from
a patient diagnosed with Prader-Willi syndrome, we found RNA expression from SNRPN, SNORD115, and SNORD116 which does
not support a genetic diagnosis of Prader-Willi syndrome. The patient was a female, Caucasian nursing home resident with history of
morbid obesity (BMI 56.3) and mental retardation. She died at age of 56 from pulmonary embolism. SNORD115 and SNORD116 are
unexpectedly stable in post mortem tissue and can be used for post-mortem diagnosis. Molecular characterization of PWS tissue donors
can confirm the diagnosis and identify those patients that have been misdiagnosed.
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Introduction

Prader-Willi syndrome (PWS) is a congenital disease
caused by the loss of RNA expression from an imprinted
region on chromosome 15. This region is expressed only
from the paternally inherited allele. Patients with PWS
typically undergo several stages beginning as infants
when they are characterized by severe infantile hypotonia with poor suck and failure to thrive. This stage is
followed by early childhood onset obesity and hyperphagia. The patients exhibit developmental delay and/or
mild intellectual disability. Other features include short
stature, hypogonadism, thick saliva, obsessive-compulsive behavior, and hormonal imbalances.1,2
Recently, several patients with Prader-Willi-like
phenotypes have been described (Fig. 1A). These
patients had microdeletions affecting two clusters of
small nucleolar RNAs (snoRNAs), SNORD115 and
SNORD116. This indicates that the loss of snoRNAs
plays a central role in the etiology of the disease
(Fig. 1A).3–5
The molecular mechanisms that link the loss of
two clusters of snoRNAs to the disease are currently
under investigation. Loss of SNORD115 could explain
hyperphagia observed in PWS patients, as SNORD115
has been shown to regulate alternative splicing of the
serotonin receptor 2C. SNORD115 helps to generate
the most active form of the receptor.6–8 No molecular
mechanisms have been established thus far demonstrating the role of SNORD116 in the generation of
PWS. It is known, however, that SNORD116 influences the expression of microRNAs hosted in the
second exon of the serotonin receptor 2C.9

SNORD115 and SNORD116 do not express
canonical C/D box snoRNAs, but are likely processed
into shorter RNAs, termed psnoRNAs,10,11 that do not
associate with the proteins typically found in C/D box
snoRNAs.10,12 Canonical C/D box snoRNAs function
in 2′-O-methylation of non-coding RNAs and form a
defined ribonuclear complex with the proteins fibrillarin, NOP56/58 and 15.5 kD (NHP2L1).
Currently, there are no mouse models available that
faithfully replicate the human phenotype13 and molecular investigations rely on human material. Since
SNORD115 is exclusively, and SNORD116 mainly,
expressed in the brain, tissue deposited in brain banks
is crucial for molecular analysis aimed to find the
cause of the disease.

Case Presentation

Patient 4876 was clinically diagnosed with PWS and
lived in group housing. The patient’s cause of death
was pulmonary embolism at the age of 56 years
(year of birth 1950). She was described as morbidly
obese with a weight of 140 kg (308 lbs) and height of
157.5 cm (5 ft, 2 in) with a body mass index (BMI)
of 56.3. She had a life long history of learning difficulties, carrying a diagnosis of mental retardation.
She was reported to have an insatiable appetite, continually seeking food. On one occasion, she ingested
5 lbs of raw hamburger meat. It was necessary to
lock food sources and as such, the refrigerator had a
chain and lock on it. She threw extreme temper tantrums when she was denied food. Medical records are
sparse, but she was reported to suffer from anxiety

A

Patient 1
Patient 2
Patient 3
Figure 1A. Overview of the snoRNA expression region on chromosome 15. Summary of the Prader-Willi syndrome region on chromosome 15q11.2-q13.
C/D box snoRNAs are indicated as SNORD and their gene number.
Notes: The SNORD116 cluster consists of 24 expression units and the SNORD115 cluster of 47 expression units and is indicated in yellow. IPW: imprinted
in Prader-Willi. Microdeletion of snoRNA expressing units that cause PWS are indicated by arrows. Patient 1,3 Patient 2,5 Patient 3.4 The sequences for the
snoRNA probes were gggtcaatgatgagaaccttatattgtcctgaagagaggtgatgacttaaaaatcatgctcaataggattacgctgaggccc for SNORD115-11 and GGACCTCAGTTCCGATGAGAACGACGGTATGAGTTCTCACTCATTTTGTTC AGCTTTTCCAAGGAATGTTTTTATGGGGGACTCATCATCGATCCA for SNORD116-3.
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Figure 1B. Overview of the snoRNA expression region on chromosome
15. RNase protection analysis of 10 µg frontal cortex RNA from PWS
patients and control patients.
Notes: As a probe, uniformly 32P-labeled antisense probes were used.
The RNA marker is 150, 100, 90, 80, 70, 60, 50, 40 and 30 nt. The cartoon on the right shows the localization of the riboprobes and the outline
of an RNase protection assay.
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Figure 1C. Overview of the snoRNA expression region on chromosome 15.
RNase protection analysis of 10 µg frontal cortex RNA from PWS and control patients using a U2 riboprobe with the sequence ATCGCTTCTCGGCCTTTTGGCTAAGATCAAGTGTAGTATCTGTTCTTATCAGT
TTAATATCTGATACGTCCTCTATCCGAGGACAATATATTAAATGGATTTTTGG
AAATAGGAGATGGAATAGGAGCTTGCTCCGTCCACTCCACGCATCGACCTG GTATTGCAGTACTTCCAGGAACGGTGCACTCTCC.
Note: U2 expresses multiple related genes, which accounts for the
additional bands.
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and have frequent falls. The frequent falls may have
been due to low muscle tone and decreased muscle
mass that is described in PWS. Additionally, the
anxiety may have contributed to her behavior problems and are usually described in PWS patients. This
patient also had Obstructive Sleep Apnea (OSA)
with chronic CO2 retention, also described in PWS
patients. Morbid obesity is also associated with
OSA, however, PWS patients have a low muscle tone
in addition to obesity that increases odds for OSA.
These described clinical features led to the diagnosis
of PWS for this patient. This diagnosis was based on
clinical criteria since, at the time, routine diagnostic
tests were not available.
The brain was removed after a post mortem interval of 41 hrs and showed no gross abnormalities.
Microscopic examination showed gliosis and deposition of dark granular material in the cerebral cortical
molecular layer and in the midbrain. There were no
observable neurofibrillary tangles, senile plaques, or
Lewy bodies. There was multifocal leptomeningeal
fibrosis. The dentate gyrus showed focal thinning and
dispersion of neurons, some of which showed degenerative features. There was loss of Purkinje cells
and Bergmann’s gliosis. The patient’s medical history included depression, mental retardation, morbid
obesity, hypothyroidism, diabetes mellitus, history
of falls, chronic CO2 retention secondary to obesity,
hypercholesterolemia, recent urinary tract infections,
and meningioma. Additional family history was
obtained following the current genetic analysis. The
donor had two sisters with the same phenotype, one
of whom is deceased.

Post-Mortem Genetic Evaluation

The brain of patient 4876 was donated to the NICHD
Brain and Tissue Bank (Baltimore, MD). We analyzed
RNA from frontal cortex by RNase protection analysis.
As a probe, we used a uniformly radiolabeled riboprobe
against chr15: 25, 318, 253-25, 318, 349 for SNORD115
and chr15: 25, 494, 345-25, 494, 426 for SNORD116
in Hg19 for SNORD115 and chr15: 25, 494, 345-25,
494, 426 for SNORD116. The RNase protections were
performed as previously described.14 RNA was isolated from brain using RNeasy Lipid Tissue Kit (Qiagen, Hilden) according to manufactory protocol. RNA
expressing constructs to make RNase protection probes
are available through Addgene (Cambridge MA).
81
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Figure 1D. Overview of the snoRNA expression region on chromosome 15. qRT-PCR analysis of SNORD116 and SNRPN expression in a cortex of PWS
and normal subjects.

As controls, we used RNA obtained from non
Prader-Willi subject tissues from the NICHD brain
bank (Table 1).
As shown in Figure 1B, patient 4876 expressed
SNORD115 and SNORD116 to the same degree
as the controls. Performing an RNase protection
assay with the ubiquitously expressed U2 snoRNA
showed approximately equal loading in each lane
(Fig. 1C).

Next, the expression of small nuclear ribonucleoprotein polypeptide N (SNRPN) that hosts SNORD115 and
SNORD116 in their 3′ UTR was analyzed (Fig. 2). We
amplified the SNRPN cDNA using primers h_SNRPN-F
ggactcccatcaagtctcca h (to exon #4) SNRPN-R tggctttaaccacctcttgg (to exon #5). Again, there was expression
of SNRPN in patient 4876, but not in PWS controls.
Quantitative (q) RT-PCR was conducted for each
of the brain tissue samples using 400 ng of total

Table 1. Overview of patient material used.
Patient
Sex
Age
Cause of
death
PMI, hours
RIN

4876
Female
56
Pulmonary embolism
(diagnosed with PWS)
41
2,3

5324
Male
18
Complications of
disorder (PWS)
22
5,9

4805
Female
39
Ischemic
bowel (PWS)
16
3,9

5238
Male
32
Morphine
intoxication
7
4,1

4782
Male
18
Head and
chest injuries
17
8,9

1539
Female
33
Multiple
injuries
23
7,5

Abbreviations: PMI, post mortem interval; RIN number (RNA integrity number) determined by capillary electrophoresis.
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Disomy
Disomy
Disomy
–
Disomy
Normal
Normal
Normal
PWS pattern
Normal
0.42
0.60
0.46
1.00
0.50
0.50
–
–
1.00
0.50
0.44
0.53
0.61
1.00
0.50
0.46
0.43
0.57
1.00
0.50
0.40
0.49
0.68
1.00
0.50
0.89
1.07
1.04
1.00
1.00
0.56
0.66
0.57
1.00
0.50
Normal
Normal
Normal
PWS
Normal

1.22
1.00
0.94
0.73
0.60
0.97
0.92
PWS

Notes: The MS-MLPA assay was conducted on 100 ng of genomic DNA for each of the brain tissue samples, according to manufacturer’s instructions (MRC Holland; Amsterdam, Netherlands).
The subjects 4805 and 4876 showed patterns compatible with disomy, possibly UPD. Subject 5324′s CYFIP probe site appears to be intact, but the probe ABPA2 site, located downstream
from BP3, appears to be missing, a pattern compatible with atypical deletion. Patient 4876 showed a normal methylation pattern.
Abbreviation: c/w, compatable with.

Brain
Brain
Brain
Brain
Brain
Control 1539
Control 4782
Control 5328
Exp. PWS
Exp. normal

pat. atyp. del.
bp2 to past
bp3
Normal
Normal
Normal
–
Normal
Brain
PWS 5324

mat. disomy
Disomy

PWS pattern
Disomy
DNA partially Disomy
degraded;
MKRN3 c/w
normal pattern
PWS pattern
Del. atypical
0.95
–
0.91
–
0.99
–
0.69
–
0.89
–
0.95
1.04
0.97
0.57

RNA, with a net final RNA concentration per reaction
of 20 ng/µl. Then, 2.5 µl of the cDNA product (approximately 50 ng of cDNA) was used for
quantitative PCR (qPCR) using TaqMan Probes
directed at the SNORD116 (custom probe) and
SNRPN (Applied Biosystems) target sites. A GAPDH
TaqMan Probe (Applied Biosystems) was used as
loading control. As shown in Figure 1D, patient 4876
had expression at SNRPN that was more than any of
the 3 control brain samples and a very robust expression at SNORD116. In contrast, the two PWS samples (4805 and 5324) had basically no expression at
SNRPN and SNORD116.
DNA methylation analysis using MethylationSpecific Multiplex Ligation-Dependent Probe
Amplification (MS-MLPA) can be used to diagnose
individuals with PWS.1 We used 100 ng of DNA for
each of the brain tissue samples, according to the
manufacturer’s instructions (MRC Holland; Amsterdam, Netherlands). Our analysis showed that patient
4876 had approximately 57% DNA methylation at
MKRN3, which would be typical for a normal control
individual and was within the range of 3 control brain
samples15 (Table 2). DNA methylation analysis at the
SNRPN locus could not be determined due to DNA
degradation from the aged brain sample.
Finally, we performed Affymetrix exon junction
array analysis using posterior hypothalamic RNA. We
compared genome wide gene expression of patient
4876, with the two molecularly confirmed PWS
patients 5324 and 4805, as well as the controls (5238,
4782, and 1539) (Table 1). For the analysis, the mean
values in the control and PWS groups were compared
with the values obtained for patient 4876. The array
analysis is shown in the supplementary files 1 and 2
as excel spreadsheets.

Table 2. Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA) of the samples.

Figure 2. RT-PCR analysis of the SNRPN gene (A) 1 µg of RNA was
reverse transcribed and amplified with the primers h_SNRPN-F ggactcccatcaagtctcca h (to exon #4) SNRPN-R tggctttaaccacctcttgg (to exon
#5) that detect snRNPN. (B) TRAK2 mRNA amplification was used as a
loading control.
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The most distinct difference between 4876 and the
two PWS samples were RNAs expressed from the
PWS critical region on chromosome 15 that showed
more than a 20 fold change. This finding is supported
by RNase protection of SNORD115 and SNORD116,
as well as the RT-PCR analysis of SNRPN. Overall
we observed 7,190 changes between patient 4876 and
PWS subjects.
The comparison between 4876 and control patients
resulted in 18,050 changes with a significant change
in expression. The high number of changes in both
experiments likely indicates differences between
individuals, rather than differences due to brain
pathology. However, the RNA from posterior hypothalamus of patient 4876 was more similar to PWS
subjects than to the control, as indicated by the lower
numbers of fold changes.

A genome wide array analysis showed that in terms
of RNA expression, patient 4876 was more similar to
PWS subjects than the genetically normal controls.
This similarity reflects the clinical phenotype where
patient 4876 was clinically similar to PWS resulting
in misdiagnosis. Due to the small sample number,
which is an intrinsic problem of using post-mortem
tissue of a rare disease, we cannot make statistically supported analyses. However, the data suggest
that some obesity syndromes have similarities with
PWS, although the basic molecular defect is clearly
different.
Our findings point out that diagnosis of patients
based on clinical phenotype may result in misdiagnosis.
Although clinical records are necessary and helpful,
genetic analysis of tissues donated for research should
be performed when feasible.

Conclusion

Acknowledgments

Patient 4876 was diagnosed with PWS because of
typical clinical demonstrations such as hyperphagia,
morbid obesity, short statue, low muscle tone, sleep
apnea, and mental retardation. No modern genetic
analysis has been performed while the patient was
alive. However, our post-mortem molecular genetic
analyses eliminate PWS as a diagnosis. Our genetic
analysis is based on the copy number of genes in the
genetic region causing the disease as well as expression of SNORD115 and SNORD116 snoRNAs. Due
to the long post mortem interval of 41 hrs, the DNA
was damaged and did not yield complete DNA methylation results for all genes of the PWS critical region.
Similarly, the RNA was degraded with an RNA integrity number (RIN) of 2.3 for patient 4876.
The low RIN indicates a relatively high level of
degradation of ribosomal RNAs, as RIN quantification
relies on ratio of long ribosomal RNA and short RNAs.
snoRNAs appear to be fairly stable, as we could detect
them using RNase protection analysis and qRT-PCR in
RNA with a high degree of degradation. This could be
due to posttranscriptional modifications or their small
size. In contrast to qPCR, RNase protection analysis
can discriminate between related copies of SNORD115
and SNORD116. In addition the technique allows absolute quantification of RNA and can be performed using
commercially available kits. Thus using RNase protection and qRT-PCR, SNORD115 and SNORD116 can
be detected in post-mortem tissue.
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Supplementary Files

Supplementary File 1. Excel spread sheet showing
the comparison between patient 4876 and two PWS
patients.
Supplementary File 2. Excel spread sheet showing the comparison between patient 4876 and three
control subjects.
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Supplementary File 3. Distances heat map of gene
expression of patient 4876, PWS patients, and normal
subjects.
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